Skip to content

Double-blind, Phase2 Study of TS-071 in Patients With Type 2 Diabetes Mellitus (Confirmatory Study of Dose-Response)

Double-blind, Phase2 Study of TS-071 in Patients With Type 2 Diabetes Mellitus (Confirmatory Study of Dose-Response)

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221156
Enrollment
275
Registered
2010-07-12
Start date
2010-07-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Sponsors

Taisho Pharmaceutical co., LTD
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Type 2 diabetes mellitus - HbA1c 6.5% to 10.0% etc.

Exclusion criteria

Exclusion criteria: - Insulin-dependent (Require insulin regularly) - Non-type 2 diabetes mellitus - Having critical heart disease, other ciruculatory disease, cerebrovascular disorder, pancreatic disease and hematologic disease etc.

Design outcomes

Primary

MeasureTime frame
HbA1c

Secondary

MeasureTime frame
Blood-sugar level, etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026